Peter Vibe Rasmussen
Overview
Explore the profile of Peter Vibe Rasmussen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tonnesen J, Pallisgaard J, Rasmussen P, Ruwald M, Lamberts M, Nouhravesh N, et al.
BMJ Open
. 2023 Jan;
13(1):e062768.
PMID: 36657765
Aims: Cancer is a well-known risk factor of venous thromboembolism (VTE). Some cancers are believed to be more thrombogenic. The purpose of this study was to investigate the characteristics of...
12.
Rasmussen P, Sakthivel T, Dalgaard F, Gislason G, Pallisgaard J, Hansen M
BMJ Open
. 2022 Dec;
12(9):e062353.
PMID: 36581981
Objectives: Atrial fibrillation (AF) is a predominant risk factor of ischaemic stroke and treatment with oral anticoagulants (OACs) is recommended in all patients with risk factors. This study sought to...
13.
Tonnesen J, Pallisgaard J, Ruwald M, Rasmussen P, Johannessen A, Hansen J, et al.
Europace
. 2022 Dec;
25(2):425-432.
PMID: 36480430
Aims: Overweight is associated with increased risk of atrial fibrillation (AF), but the impact of overweight and AF recurrence after ablation is less clear. Despite this, an increasing number of...
14.
Holt A, Strange J, Rasmussen P, Blanche P, Nouhravesh N, Jensen M, et al.
Am J Med
. 2021 Dec;
135(5):595-602.e5.
PMID: 34861201
Background: Bleeding safety in relation to use of systemic fluconazole and topical azoles among patients with atrial fibrillation treated with apixaban, rivaroxaban, or dabigatran is insufficiently explored, despite clinical relevance...
15.
Nyholm B, Ghouse J, Lee C, Rasmussen P, Pietersen A, Hansen S, et al.
Heart Rhythm
. 2021 Oct;
19(2):252-259.
PMID: 34673253
Background: Fascicular heart blocks can progress to complete heart blocks, but this risk has not been evaluated in a large general population. Objective: The purpose of this study was to...
16.
Rasmussen P, Blanche P, Dalgaard F, Gislason G, Torp-Pedersen C, Tonnesen J, et al.
Am Heart J
. 2021 Oct;
244:42-49.
PMID: 34666012
Background: Electrical cardioversion (ECV) is a common procedure for terminating atrial fibrillation (AF). ECV is associated with brady-arrhythmic events, however, the age-specific risks of clinically significant brady-arrhythmic events are unknown....
17.
Holt A, Blanche P, Zareini B, Rasmussen P, Strange J, Rajan D, et al.
Heart
. 2021 Aug;
108(8):626-632.
PMID: 34389550
Objective: Gastrointestinal bleeding (GIB) risk in relation to concomitant treatment with non-vitamin K oral anticoagulants (NOAC) and oral glucocorticoids is insufficiently explored. We aimed to investigate the short-term risk following...
18.
Rasmussen P, Hylek E
Eur Heart J
. 2021 Aug;
42(40):4138-4140.
PMID: 34347053
No abstract available.
19.
Strange J, Holt A, Blanche P, Gislason G, Torp-Pedersen C, Christensen D, et al.
Eur Heart J
. 2021 Jul;
42(30):2899-2908.
PMID: 34245252
Aims: Reports have suggested an increased risk of aortic and mitral regurgitation associated with oral fluoroquinolones (FQs) resulting in a safety warning published by the European Medicines Agency (EMA). However,...
20.
Dsouza M, Nielsen D, Marie Svane I, Iversen K, Rasmussen P, Madelaire C, et al.
Eur Heart J
. 2020 Dec;
42(16):1621-1631.
PMID: 33291147
Aims: The study aimed to estimate the risk of cardiac events in immune checkpoint inhibitor (ICI)-treated patients with lung cancer or malignant melanoma. Methods And Results: The study included consecutive...